Catalyst Pharmaceuticals (CPRX) Other Operating Expenses (2019 - 2026)

Catalyst Pharmaceuticals' Other Operating Expenses history runs 8 years deep, the most recent figure standing at $24.2 million for Q1 2026.

• Quarterly Other Operating Expenses fell 11.29% year-over-year to $24.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $121.7 million (up 9.01% YoY) and the FY2025 annual result came in at $124.8 million, up 17.44% from the prior year.
• Other Operating Expenses was $24.2 million for Q1 2026 at Catalyst Pharmaceuticals, down from $35.5 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $35.5 million in Q4 2025 and bottomed at $5.9 million in Q1 2022.
• A 5-year average of $22.1 million and a median of $24.2 million in 2026 frame the typical range for Other Operating Expenses.
• Annual changes were most pronounced in 2023 — Other Operating Expenses soared 179.75% — and 2026, when it slipped 11.29%.
• Catalyst Pharmaceuticals' Other Operating Expenses stood at $11.8 million in 2022, then jumped by 111.19% to $24.9 million in 2023, then grew by 24.61% to $31.0 million in 2024, then gained by 14.69% to $35.5 million in 2025, then tumbled by 31.97% to $24.2 million in 2026.
• Business Quant data shows CPRX's Other Operating Expenses at $24.2 million in Q1 2026, $35.5 million in Q4 2025, and $32.0 million in Q3 2025.